Stockreport

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio, Inc.  (PASG) 
PDF Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 [Read more]